Teva appoints Christine Fox as EVP U.S. Commercial; Sven Dethlefs departing Nov 17

TEVA PHARMACEUTICAL INDUSTRIES LTD

Sven Dethlefs, EVP North America Commercial, to leave Teva on November 17, 2023 after 15 years.
Christine Fox appointed EVP U.S. Commercial; previously Global President, Gene Therapies at Novartis.
Fox brings 30+ years industry experience from Novartis, Amgen, Merck, Takeda.
CEO Richard Francis thanked Dethlefs and expressed confidence in Fox's ability to lead U.S. business.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sven Dethlefs

Executive Vice President, North America Commercial

TEVA · TEVA PHARMACEUTICAL INDUSTRIES LTD

Effective: 2023-11-17
Filed: September 28, 2023, 7:59 PM ET

Dr. Sven Dethlefs, Executive Vice President, North America Commercial, will be leaving Teva.

Appointed

Christine Fox

Executive Vice President, U.S. Commercial

TEVA · TEVA PHARMACEUTICAL INDUSTRIES LTD

Filed: September 28, 2023, 7:59 PM ET

Ms. Christine Fox will be appointed as Executive Vice President, U.S. Commercial.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Sven Dethlefs departed as Executive Vice President, North America Commercial at TEVA PHARMACEUTICAL INDUSTRIES LTD.

Action: leaving
Role: Executive Vice President, North America Commercial

Exact text from the filing

Dr. Sven Dethlefs, Executive Vice President, North America Commercial, will be leaving Teva.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Christine Fox was appointed as Executive Vice President, U.S. Commercial at TEVA PHARMACEUTICAL INDUSTRIES LTD.

Action: appointed
Role: Executive Vice President, U.S. Commercial

Exact text from the filing

Ms. Christine Fox will be appointed as Executive Vice President, U.S. Commercial.

View on SEC.gov

TEVA PHARMACEUTICAL INDUSTRIES LTD filing history →

Source: SEC EDGAR

accession 0001193125-23-245614

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.